Summary

Effects of Growth Hormone on Body Composition and Cardiovascular Risk Markers in Women with Visceral Adiposity was a 6-month randomized, double-blind, placebo-controlled trial to determine whether low-dose GH administration would reduce abdominal adiposity and CV risk markers in premenopausal women with reduced GH secretion due to abdominal obesity.